AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

AbbVie closed out the year on a high note, as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s ...

Discover how to navigate inflation with long-term investments in resilient companies like Coca-Cola, AbbVie, and TC Energy.

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

International musician Mark Williams is returning home to Northland with a headline performance at the Waitangi Vibes ...

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...

Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.

Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10.

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...

These characteristics make dividend growth stocks compelling investments in any market environment. The strategy's success ...